Trials / Completed
CompletedNCT04938141
MEOI and HRQoL in CLL Patients Treated With BTKis
Medical Events of Interest and Health-Related Quality of Life in Chronic Lymphocytic Leukemia Patients Initiating Treatment With Bruton's Tyrosine Kinase Inhibitors Acalabrutinib or Ibrutinib
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 23 (actual)
- Sponsor
- AstraZeneca · Industry
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
This is a multi-site observational study of medical events of interest (MEOI) and health-related quality of life (HRQoL) in chronic lymphocytic leukemia (CLL) patients initiating treatment with the Bruton's tyrosine kinase inhibitors (BTKi) acalabrutinib or ibrutinib in the United States (US)
Conditions
Timeline
- Start date
- 2021-10-07
- Primary completion
- 2024-09-26
- Completion
- 2024-09-26
- First posted
- 2021-06-24
- Last updated
- 2025-05-21
Locations
16 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT04938141. Inclusion in this directory is not an endorsement.